Hepatic Disease in Patients With HIV
Summary
- In persons coinfected with HIV and HCV, the prevalence of steatosis ranges from 40% to 70%, with higher rates observed among persons with significant hepatic fibrosis, HCV genotype 3, and exposure to NRTIs didanosine and stavudine[Macías 2012; Sulkowski 2005; Miller 2000; McGovern 2006; Marks 2005]
- Since these drugs are no longer used, this risk is diminished compared with previous times. However, many older patients will undoubtedly have been exposed to these drugs in earlier regimens
- Patients with HIV receiving ART may be at increased risk for the development of NAFLD, particularly in the setting of obesity
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content